A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study Of PF-04447943 In Subjects With Mild To Moderate Alzheimer's Disease.
Phase of Trial: Phase II
Latest Information Update: 12 Dec 2017
At a glance
- Drugs PF 4447943 (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors Pfizer
- 12 Dec 2017 Results assessing safety and tolerability of PF-04447943 across a clinical trial program in 277 patients (Eight phase 1 studies, One phase II and One phase Ib study) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 13 Oct 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Sep 2010 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History